Haematologica 2000;85:supplement to no. 10 - Supplements ...

More documents

Recommendations

Info

Haematologica IMMUNE TOLERANCE IN HEMOPHILIA AND THE TREATMENT OF HEMOPHILIACS WITH AN INHIBITOR Palermo, October 1999 Foreword Mariani, G. (Palermo, Italy), Brackmann, H.H. (Bonn, Germany) . . . . . . . . . . . . . . . . . . . 1 Epidemiology and Treatment of FVIII and IX Inhibitors FVIII Inhibitors with Recombinant Products Lusher, J.M. (Detroit, USA) . . . . . . . . . . . . . . . . . . . 2-6 Risk Factors for Inhibitor Development Oldenburg, J., Schwaab, R. (Bonn, Germany). 7-14 Strategies for the Treatment of Inhibitor Patients Ingerslev J. (Aarhus, Denmark). . . . . . . . . . 15-20 Porcine FVIII, Past, Present and Future Hay, C. (Manchester, UK). . . . . . . . . . . . . . . . . . 21-25 Mapping Factor VIII Inhibitor Epitopes Using Hybrid Human/Porcine Factor VIII Molecules Lollar, P. (Atlanta, USA) . . . . . . . . . . . . . . . . . . . 26-30 Antibodies to FIX Warrier, I. (Detroit, USA). . . . . . . . . . . . . . . . . . . 31-34 Clinical and Organisational Aspects Related to Immunetolerance Protocols Regimes of factor VIII Administration: Continuous vs. Bolus Berntorp, E. (Malmoe, Sweden). . . . . . . . . . . . 69-72 Immunetolerance by Intermittent Factor VIII Boluses in two High Responder H.A. Patients Landolfi, R. (Rome, Italy) . . . . . . . . . . . . . . . . . . 73-74 Side Effects Brackmann, H.H. (Bonn, Germany). . . . . . . . . 75-77 Immunetolerance: A Nursing Perspective Butler, R.B. (Philadelphia, USA). . . . . . . . . . . . 78-80 Immunetolerance: The Parent’s Perspective Gargallo, B. (Rome, Italy) . . . . . . . . . . . . . . . . . . 81-82 Immune Tolerance Induction: Treatment Duration Analysis and Economic Considerations Aledort, L.M. (New York, USA), Kroner, B. (Rockville, USA), Mariani, G. (Palermo, Italy) . . . . . . . . . . . . . . . . . 83-85 2000 vol. 85 supplement to no. 10 CONTENTS (indexed by Current Contents/Life Sciences and in Faxon Finder and Faxon XPRESS, also available on diskette with abstracts) 1 Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors Ewenstein, B.M. (Boston, USA) . . . . . . . . . . . . 35-39 Registries of Immunetolerance Protocols The Maintenence of Tolerance after Successful ITT induction in Hemophilia A and B: The North American Registry Di Michele, D. (New York, USA) . . . . . . . . . . . . 40-44 The German Registry of ITT in Hemophilia: 1999 Update Lenk, H. ( Dresden, Germany) . . . . . . . . . . . . . 45-47 Malmoe Protocol Update Berntorp, E. (Malmoe, Sweden). . . . . . . . . . . . 48-51 Immunetolerance Induction: Prospective Clinical Trials Hay, C.R.M. (Manchester, UK). . . . . . . . . . . . . . 52-56 Acquired Factor VIII Inhibitors Acquired Factor VIII Auto Antibody Inhibitors: Current Concepts and Potential Therapeutic Strategies for the Future Kessler, C.M. (Washington, USA). . . . . . . . . . . 57-63 New Protocol for Immunetolerance Induction in Acquired Hemophilia Nemes, L. (Budapest, Hungary). . . . . . . . . . . . 64-68 Immunetolerance: Molecular and Biological Aspects Characterisation of Antibodies to FVIII in Hemophilia Patients Treated by Immunetolerance Therapy Scandella, D. (Rockville, USA) . . . . . . . . . . . . . 86-88 FVIII Inhibitor with Catalytic activity towards FVIII Lacroix-Desmazes, S. Kazatchkine M.D. (Paris, France) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89-92 B and T Cell Tolerance: From Basic Concepts to Clinical Practice Saint Remy, J.M. (Leuven, Belgium) . . . . . . . . 93-96 Idiotypic Regulation of Anti Factor VIII Antibodies Kazatchkine, M.D., Lacroix Demazes, S. (Paris, France). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97-99 Immune Response to Factor VIII in Hemophilia A Mice Hoyer, L. (Rockville, USA) . . . . . . . . . . . . . . . 100-102 Animal Models to Explore Tolerance Induction to FVIII Gilles, J. (Leuven, Belgium) . . . . . . . . . . . . . 103-107 Gene Therapy, Factor VIII Inhibitors and Immunetolerance: Hopes and Concerns Lillicrap, D. (Kingston, Canada) . . . . . . . . . . 108-112 Immunological Tolerance: A Clinical Perspective White, G. (Chapel Hill, USA) . . . . . . . . . . . . . 113-116
Acknowledgments We wish to thank the Authors for their contributions and all those who made the publication of the Proceedings possible, in particular Mr. Michael Briggs for his help in the transcription/revision work. The editing of the Proceedings of the III Workshop on Immune Tolerance was supported by an unrestricted grant by Baxter. The Publication costs were supported by an unrestricted grant by Aventis Behring. Forthcoming Workshop The fourth Workshop on Immune Tolerance will take place in Bonn, Germany, Thursday August 30th through September 1st 2001. Information concerning the site and the programme will be circularized later
Page 1: Haematologica established in 1920 e
Page 5 and 6: Haematologica 2000; 85(suppl. to n.
Page 7 and 8: 4 J.M. Lusher (range 1-34) for pati
Page 9 and 10: 6 J.M. Lusher ALEDORT: I’d just l
Page 11 and 12: 8 J. Oldenburg et al. Tuddenham et
Page 13 and 14: 10 J. Oldenburg et al. Table 4. Mut
Page 15 and 16: 12 J. Oldenburg et al. reactions ac
Page 17 and 18: 14 J. Oldenburg et al. Dr. Schwaab
Page 19 and 20: 16 J. Ingerslev be established more
Page 21 and 22: 18 J. Ingerslev sion monitoring dem
Page 23 and 24: 20 J. Ingerslev REFERENCES 1. Hay C
Page 25 and 26: 22 CRM Hay Side effects of Hyate:C
Page 27 and 28: 24 CRM Hay tion by porcine factor V
Page 31 and 32: 28 P. Lollar these epitopes by site
Page 33 and 34: 30 P. Lollar titer and an anti-porc
Page 35 and 36: 32 Immune Tolerance and the Treatme
Page 37 and 38: 34 Immune Tolerance and the Treatme
Page 39 and 40: 36 B.M. Ewenstein et al. exposed, 7
Page 41 and 42: 38 B.M. Ewenstein et al. Table 1. H
Page 45 and 46: 42 D. DiMichele et al. Discussion T
Page 47 and 48: 44 D. DiMichele et al. Italy and in
Page 49 and 50: 46 H. Lenk et al. Figure 1. Maximum
Page 53 and 54:
50 E. Berntorp et al. standing inhi
Page 55 and 56:
Haematologica 2000; 85(suppl. to n.
Page 57 and 58:
54 C.R.M. Hay Logistic barriers to
Page 59 and 60:
56 C.R.M. Hay ed to go for a fully
Page 61 and 62:
58 C.M. Kessler hemophilia A, have
Page 63 and 64:
60 C.M. Kessler in eradicating allo
Page 65 and 66:
62 C.M. Kessler ously. Do you see d
Page 67 and 68:
Page 69 and 70:
66 L. Nemes et al. Figure 1. A gian
Page 71 and 72:
68 L. Nemes et al. trast to the ear
Page 73 and 74:
70 E. Berntorp Hemophilia A severe
Page 75 and 76:
72 E. Berntorp VIII. MARIANI: It wo
Page 77 and 78:
74 R. Landolfi et al. Table 1. Resu
Page 79 and 80:
76 H-H. Brackmann et al. Table 1a.
Page 81 and 82:
Page 83 and 84:
80 R.B. Butler of progress and perm
Page 85 and 86:
82 B. Gargallo emotional consequenc
Page 87 and 88:
84 L.M. Aledort et al. Success rate
Page 89 and 90:
Page 91 and 92:
88 D. Scandella et al. Seven non-in
Page 93 and 94:
90 S. Lacroix-Desmazes et al. demon
Page 95 and 96:
92 S. Lacroix-Desmazes et al. 244:1
Page 97 and 98:
94 J-M.R. Saint-Remy linking of sur
Page 99 and 100:
96 J-M.R. Saint-Remy identification
Page 101 and 102:
98 M.D. Kazatchkine et al. normal l
Page 103 and 104:
Page 105 and 106:
102 L.W. Hoyer et al. have prevente
Page 107 and 108:
104 J.G. Gilles et al. Table 1. The
Page 109 and 110:
106 J.G. Gilles et al. typic intera
Page 111 and 112:
Page 113 and 114:
110 D. Lillicrap a transgene in tis
Page 115 and 116:
112 D. Lillicrap DI MICHELE: I am a
Page 117 and 118:
114 G.C. White et al. cost, time, a
Page 119 and 120:
116 G.C. White et al. Blood 62:141-
Page 121:
II Immune Tolerance and the Treatme
show all

Haematologica 2000;85:supplement to no. 10 - Supplements ...

Create successful ePaper yourself

Delete template?

Save as template?